Matsuno H, Okada K, Ueshima S, Matsuo O, Kozawa O
Department of Pharmacology, Gifu University School of Medicine, Tsukasa-machi, Gifu, Japan.
J Thromb Haemost. 2003 Aug;1(8):1734-9. doi: 10.1046/j.1538-7836.2003.00252.x.
The importance of pulmonary embolism (PE) due to venous thrombosis is recognized in the treatment of vascular diseases. We have investigated the physiological effects of plasmin generation in experimental acute PE using mice deficient in plasminogen (Plg-/-) or alpha2-antiplasmin (alpha2-AP-/-). PE was induced by continuous induction of venous thrombus in the left jugular vein by endothelial injury due to photochemical reaction. The mortality of wild-type mice was 68.8% at 2 h after the initiation of venous thrombosis and it was significantly reduced in alpha2-AP-/- mice (41.7%). In contrast, Plg-/- mice did not survive. Histological evidence of thromboembolism in the lung was obtained in all mice. However, whereas a strict thromboembolism was observed in Plg-/- mice, only a few thrombi were detected in the lungs of alpha2-AP-/- mice. Plasma fibrinogen levels measured in mice were not different. When alpha2-AP was infused in alpha2-AP-/- mice, the mortality was indistinguishable from wild-type mice. Tissue-type plasminogen activator (tPA) did not reduce the mortality due to acute PE in wild-type mice. However, in alpha2-AP-/- mice, tPA (0.52 mg x kg-1) significantly decreased the mortality compared with that of alpha2-AP-/- mice without tPA. The bleeding time was not significantly prolonged in either type of mice treated with tPA. The lack of plasminogen increases the mortality due to acute PE while a lack of alpha2-AP decreases the mortality rate, which can be further reduced by tPA administration. Therefore, the combination of inhibition of alpha2-AP with thrombolytic therapy could be beneficial in the treatment of acute PE.
静脉血栓形成所致肺栓塞(PE)在血管疾病治疗中的重要性已得到认可。我们利用缺乏纤溶酶原(Plg-/-)或α2-抗纤溶酶(α2-AP-/-)的小鼠,研究了实验性急性肺栓塞中纤溶酶生成的生理效应。通过光化学反应引起内皮损伤,在左颈静脉持续诱导静脉血栓来诱发肺栓塞。静脉血栓形成开始后2小时,野生型小鼠的死亡率为68.8%,而α2-AP-/-小鼠的死亡率显著降低(41.7%)。相比之下,Plg-/-小鼠未能存活。所有小鼠均获得了肺部血栓栓塞的组织学证据。然而,Plg-/-小鼠中观察到严重的血栓栓塞,而α2-AP-/-小鼠的肺部仅检测到少量血栓。所测小鼠血浆纤维蛋白原水平并无差异。当给α2-AP-/-小鼠输注α2-AP时,其死亡率与野生型小鼠无差异。组织型纤溶酶原激活剂(tPA)并未降低野生型小鼠急性肺栓塞所致的死亡率。然而,在α2-AP-/-小鼠中,与未用tPA的α2-AP-/-小鼠相比,tPA(0.52 mg·kg-1)显著降低了死亡率。两种用tPA治疗的小鼠的出血时间均未显著延长。缺乏纤溶酶原会增加急性肺栓塞所致的死亡率,而缺乏α2-抗纤溶酶则会降低死亡率,通过给予tPA可进一步降低死亡率。因此,α2-抗纤溶酶抑制与溶栓治疗联合应用可能对急性肺栓塞的治疗有益。